We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Astellas to Form Strategic Partnership with ClearPath to Build Vaccine Portfolio

News   Jan 07, 2014

 
Astellas to Form Strategic Partnership with ClearPath to Build Vaccine Portfolio
 
 
 

RELATED ARTICLES

‘Shortcut’ Transforms Terpene Biosynthesis in E. Coli

News

Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.

READ MORE

Poo Transplant Shows Promise in Prelim Study for Ulcerative Colitis

News

Anaerobically prepared fecal microbiota transplantation improved remission rates in people with moderately active ulcerative colitis at 8 weeks. Further research is needed to assess longer-term efficacy and safety.

READ MORE

Concern Over Fake ISO 9001 Accreditation of Chinese Companies

News

A study concludes that fake ISO 9001 quality certificates are very widespread across Chinese companies and that the certification processes of the auditing companies lack credibility.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE